• Je něco špatně v tomto záznamu ?

A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer

T. Ganguly, S. Dannoon, MR. Hopkins, S. Murphy, H. Cahaya, JE. Blecha, S. Jivan, CR. Drake, C. Barinka, EF. Jones, HF. VanBrocklin, CE. Berkman,

. 2015 ; 42 (10) : 780-7. [pub] 20150609

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem, Research Support, U.S. Gov't, Non-P.H.S.

Perzistentní odkaz   https://www.medvik.cz/link/bmc16020546

INTRODUCTION: In this study, a structurally modified phosphoramidate scaffold, with improved prostate-specific membrane antigen (PSMA) avidity, stability and in vivo characteristics, as a PET imaging agent for prostate cancer (PCa), was prepared and evaluated. METHODS: p-Fluorobenzoyl-aminohexanoate and 2-(3-hydroxypropyl)glycine were introduced into the PSMA-targeting scaffold yielding phosphoramidate 5. X-ray crystallography was performed on the PSMA/5 complex. [(18)F]5 was synthesized, and cell uptake and internalization studies were conducted in PSMA(+) LNCaP and CWR22Rv1 cells and PSMA(-) PC-3 cells. In vivo PET imaging and biodistribution studies were performed at 1 and 4 h post injection in mice bearing CWR22Rv1 tumor, with or without blocking agent. RESULTS: The crystallographic data showed interaction of the p-fluorobenzoyl group with an arene-binding cleft on the PSMA surface. In vitro studies revealed elevated uptake of [(18)F]5 in PSMA(+) cells (2.2% in CWR22Rv1 and 12.1% in LNCaP) compared to PSMA(-) cells (0.08%) at 4 h. In vivo tumor uptake of 2.33% ID/g and tumor-to-blood ratio of 265:1 was observed at 4 h. CONCLUSIONS: We have successfully synthesized, radiolabeled and evaluated a new PSMA-targeted PET agent. The crystal structure of the PSMA/5 complex highlighted the interactions within the arene-binding cleft contributing to the overall complex stability. The high target uptake and rapid non-target clearance exhibited by [(18)F]5 in PSMA(+) xenografts substantiates its potential use for PET imaging of PCa. ADVANCES IN KNOWLEDGE: The only FDA-approved imaging agent for PCa, Prostascint®, targets PSMA but suffers from inherent shortcomings. The data acquired in this manuscript confirmed that our new generation of [(18)F]-labeled PSMA inhibitor exhibited promising in vivo performance as a PET imaging agent for PCa and is well-positioned for subsequent clinical trials. Implications for Patient Care Our preliminary data demonstrate that this tracer possesses the required imaging characteristics to be sensitive and specific for PCa imaging in patients at all stages of the disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020546
003      
CZ-PrNML
005      
20160801123815.0
007      
ta
008      
160722s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.nucmedbio.2015.06.003 $2 doi
024    7_
$a 10.1016/j.nucmedbio.2015.06.003 $2 doi
035    __
$a (PubMed)26169882
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ganguly, Tanushree $u Department of Chemistry, Washington State University, USA.
245    12
$a A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer / $c T. Ganguly, S. Dannoon, MR. Hopkins, S. Murphy, H. Cahaya, JE. Blecha, S. Jivan, CR. Drake, C. Barinka, EF. Jones, HF. VanBrocklin, CE. Berkman,
520    9_
$a INTRODUCTION: In this study, a structurally modified phosphoramidate scaffold, with improved prostate-specific membrane antigen (PSMA) avidity, stability and in vivo characteristics, as a PET imaging agent for prostate cancer (PCa), was prepared and evaluated. METHODS: p-Fluorobenzoyl-aminohexanoate and 2-(3-hydroxypropyl)glycine were introduced into the PSMA-targeting scaffold yielding phosphoramidate 5. X-ray crystallography was performed on the PSMA/5 complex. [(18)F]5 was synthesized, and cell uptake and internalization studies were conducted in PSMA(+) LNCaP and CWR22Rv1 cells and PSMA(-) PC-3 cells. In vivo PET imaging and biodistribution studies were performed at 1 and 4 h post injection in mice bearing CWR22Rv1 tumor, with or without blocking agent. RESULTS: The crystallographic data showed interaction of the p-fluorobenzoyl group with an arene-binding cleft on the PSMA surface. In vitro studies revealed elevated uptake of [(18)F]5 in PSMA(+) cells (2.2% in CWR22Rv1 and 12.1% in LNCaP) compared to PSMA(-) cells (0.08%) at 4 h. In vivo tumor uptake of 2.33% ID/g and tumor-to-blood ratio of 265:1 was observed at 4 h. CONCLUSIONS: We have successfully synthesized, radiolabeled and evaluated a new PSMA-targeted PET agent. The crystal structure of the PSMA/5 complex highlighted the interactions within the arene-binding cleft contributing to the overall complex stability. The high target uptake and rapid non-target clearance exhibited by [(18)F]5 in PSMA(+) xenografts substantiates its potential use for PET imaging of PCa. ADVANCES IN KNOWLEDGE: The only FDA-approved imaging agent for PCa, Prostascint®, targets PSMA but suffers from inherent shortcomings. The data acquired in this manuscript confirmed that our new generation of [(18)F]-labeled PSMA inhibitor exhibited promising in vivo performance as a PET imaging agent for PCa and is well-positioned for subsequent clinical trials. Implications for Patient Care Our preliminary data demonstrate that this tracer possesses the required imaging characteristics to be sensitive and specific for PCa imaging in patients at all stages of the disease.
650    _2
$a amidy $x chemie $7 D000577
650    _2
$a zvířata $7 D000818
650    _2
$a antigeny povrchové $x chemie $7 D000954
650    _2
$a biologický transport $7 D001692
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a stabilita léku $7 D004355
650    12
$a radioizotopy fluoru $7 D005462
650    _2
$a glutamátkarboxypeptidasa II $x antagonisté a inhibitory $x chemie $7 D043425
650    _2
$a lidé $7 D006801
650    _2
$a inhibiční koncentrace 50 $7 D020128
650    _2
$a izotopové značení $7 D007553
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a molekulární modely $7 D008958
650    _2
$a peptidomimetika $x chemie $x metabolismus $x farmakokinetika $x farmakologie $7 D057786
650    _2
$a kyseliny fosforečné $x chemie $7 D010756
650    _2
$a pozitronová emisní tomografie $x metody $7 D049268
650    _2
$a nádory prostaty $x patologie $x radioizotopová diagnostika $7 D011471
650    _2
$a inhibitory proteas $x chemie $x metabolismus $x farmakokinetika $x farmakologie $7 D011480
650    _2
$a konformace proteinů $7 D011487
650    _2
$a tkáňová distribuce $7 D014018
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
700    1_
$a Dannoon, Shorouk $u Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA.
700    1_
$a Hopkins, Mark R $u Department of Chemistry, Washington State University, USA.
700    1_
$a Murphy, Stephanie $u Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA.
700    1_
$a Cahaya, Hendry $u Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA.
700    1_
$a Blecha, Joseph E $u Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA.
700    1_
$a Jivan, Salma $u Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA.
700    1_
$a Drake, Christopher R $u Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA.
700    1_
$a Barinka, Cyril $u Institute of Biotechnology, CR, Prague.
700    1_
$a Jones, Ella F $u Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA.
700    1_
$a VanBrocklin, Henry F $u Department of Radiology and Biomedical Imaging, University of CA, San Francisco, USA.
700    1_
$a Berkman, Clifford E $u Department of Chemistry, Washington State University, USA; Cancer Targeted Technology, USA. Electronic address: cberkman@wsu.edu.
773    0_
$w MED00008576 $t Nuclear medicine and biology $x 1872-9614 $g Roč. 42, č. 10 (2015), s. 780-7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26169882 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20160801124043 $b ABA008
999    __
$a ok $b bmc $g 1155216 $s 945074
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 42 $c 10 $d 780-7 $e 20150609 $i 1872-9614 $m Nuclear medicine and biology $n Nucl Med Biol $x MED00008576
LZP    __
$a Pubmed-20160722

Najít záznam

Citační ukazatele

Možnosti archivace